A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients

Summary

The objective of this study was to evaluate the safety profile of ELIGARD® in ethnic Asian prostate cancer patients.

Timeline

Start

2017-06-23

Primary completion

2019-11-19

Completion

2019-11-19

Publications

• Malek R, Wu ST, Serrano D, Tho T, Umbas R, Teoh J, Lojanapiwat B, Ong TA, On WK, Thai SM, Kim J, Pophale R, Chiong E. ELIGANT: a Phase 4, interventional, safety study of leuprorelin acetate (ELIGARD(R)) in Asian men with prostate cancer. Transl Androl Urol. 2022 Feb;11(2):179-189. doi: 10.21037/tau-21-723.

Drugs

Indications